Across the nation, primary care practices that were already struggling are closing, victims of the pandemic’s financial fallout. And this is reducing access to health care, especially in rural and other regions already short on doctors.
A Trump administration maneuver allows executives who are leading the federal effort to keep investments in drug companies that would benefit from the pandemic response.
COVID-19 cases are surging across the U.S., and most workplaces are still open for business. As workers fear catching the disease while on the clock, why aren’t more companies footing the bill for testing employees?
Small-business owners struggling to remain afloat are increasingly defying new shutdown orders, in some cases pointing to Gov. Gavin Newsom’s French Laundry dinner as a reason not to comply.
Critically ill rural patients are often sent to city hospitals for high-level treatment, and as their numbers grow, some urban hospitals are buckling under the added strain. Meanwhile, mask-wearing and other pandemic prevention measures remain spotty in rural counties.
COVID-19’s toll weighs heavily on nurses, who can suffer stress and other psychological problems if they don’t believe they are able to help their patients sufficiently.
A proposal in Washington state would use right-to-try laws to allow terminally ill patients access to psilocybin — the famed magic mushrooms of America’s psychedelic ’60s — to ease depression and anxiety.
A shortage of nurses has turned hospital staffing into a sort of national bidding war, with hospitals willing to pay exorbitant wages to secure the nurses they need. That threatens to shift the supply of nurses toward more affluent areas.
The law will ban the manufacture and sale in California of personal care products that contain 24 toxics, including asbestos, formaldehyde and lead, and is expected to fill a gap in federal regulation as companies sell the new formulations nationwide.